Therapeutics/Diagnostics News

Study findings support performing surveillance colonoscopy 7 to 10 years after detection and polypectomy of baseline non-advanced adenoma rather than at 5 years, researchers wrote in the Journal of Gastroenterology and Hepatology.

BOSTON — LPCN 1148, an oral androgen receptor agonist, improved sarcopenia, hepatic encephalopathy and other biomarkers associated with end-stage liver disease among men with advanced cirrhosis and clinical decompensation.

BOSTON — Pegozafermin improved fibrosis and other key noninvasive tests at 24 weeks in patients with metabolic dysfunction-associated steatohepatitis-related cirrhosis, according to data presented at The Liver Meeting.

A combination of vedolizumab, adalimumab and methotrexate resulted in endoscopic remission at week 26 in more than a third of patients with Crohn’s disease, according to data in Clinical Gastroenterology and Hepatology.

BOSTON — Treatment with aldafermin 3 mg appeared to be well-tolerated and significantly reduced Enhance Liver Fibrosis score after 48 weeks among patients with metabolic dysfunction-associated steatohepatitis, according to a presenter.

Fecal calprotectin and serum C-reactive protein biomarkers can inform disease management for patients with asymptomatic or symptomatic Crohn’s disease, according to an updated clinical practice guideline from the AGA.

BOSTON — In a Healio video exclusive, Pam Vig, PhD, reports late-breaking data that show Livmarli improved liver health and maintained symptom response over 2 years among pediatric patients with progressive familial cholestasis.

BOSTON — Treatment with TERN-501, a selective thyroid hormone receptor beta agonist, reduced liver fat content and fibro-inflammation among patients with presumed metabolic dysfunction-associated steatohepatitis, late-breaking data showed.

BOSTON — Mortality rates were consistently lower in patients with severe alcohol-associated hepatitis treated with steroids during vs. before the COVID-19 pandemic, suggesting infection mitigation may have benefited this population.

VANCOUVER, British Columbia — More than 50% of patients with Crohn’s disease who did not achieve clinical response at week 12 to IV Tremfya achieved response at week 48 after continuing subcutaneous therapy, according to a presenter.